To: William L. Molair II who wrote (7588 ) 10/29/1998 10:10:00 PM From: ouija Respond to of 17367
I've read CTSL for over 10 years. You would be hard pressed to find anyone with the knowledge base that Michael has in these stocks, in addition to the correct sense to go against the crowd. But, Michael is not a timer, and often starts buying well before the bottom. He is long term. He does not trade. As long as a company is executing correctly, he will stand behind them, and even give them a little rope. Sometime he lets out too much rope. And he will never hold a momentum stock as it climbs into overpriced territory. The bottom line I think is as follows. Watch his recommendations for technical entry points if you are not prepared to ignore the stock after buying it. Also, understand that he often buys down and out stocks so when they turn, they may not be rocketships. Be prepared to trade half positions when you see the opportunity, especially in the biotechs. This can make you a lot of money while you wait for the core positions to play out into big winners down the road. Otherwise you would have just sat and watched as a great company like Vical goes up and down many times over the years on the way to being what I think will be a big winner. And, when Mike pounds the table on the hotline for a particular stock because of an upcoming event, that can often be a big opportunity, but you have to decide if it is just a deal that will blip the stock for a trade or the last hurdle to an important change in fundamentals. In the case of Xoma I think Mike has it right. And the fundamentals are so potenially explosive, that this is truly a 10-bagger plus in my opinion over the next year or two. The recent market turbulence has created a lot of similar opportunities in the biotech area like LGND, DUSA, and CEPH which are all in the boat of having products extremely close to market (past phase III or even 'approvable') and/or appearing to have extraordinarily positive results.